

Marco L. Lolli

Prof Marco L. Lolli is an internationally recognized expert in *Medicinal Chemistry* specialized in *hit-to-lead* optimization process and the design of bioactive using innovative bioisosteric tools.

His major research interests in Drug Design are: *broad-spectrum antivirals* (SARS-CoV-2 and other CoVs), *cancer* (Leukemia, Breast and Prostatic cancer), *neglected diseases* (Malaria, Leishmaniasis, ...) and *Neurotransmission* (Gaba and Glu).

After a Master's degree in chemistry, he has been trained in prestigious national (*Istituto Ricerche Farmacologiche "Mario Negri", Bracco Industria Chimica s.p.a, Research and Development Division*) and foreigners (*College of Pharmacy, The Ohio State University, Columbus, OH, (USA), School of Pharmacy - University of Wisconsin at Madison, Madison (WI, USA)*) laboratories. Since 2022, he is **Associate Professor in Medicinal Chemistry** (03/D1) at the *Dept of Science and Drug Technology* of the University of Turin. In February 2022, he also obtained **National Scientific Qualification (ASN) as Full Professor in Medicinal Chemistry** (03/D1, February 1th, 2022 - February 1th, 2031).



He has been **Visiting Professor** in Eu (*Denmark, Sweden, UK*) and no-Eu countries (*Bolivia, India, US*) countries, and **responsible of Erasmus agreements**: Bradford (UK), Gent (B), Lund (S), Copenhagen (DK), *University of San Andreas* (UMSA, La Paz, Bolivia) and the *Nirma University* (Ahmedabad, India).

Since 2012, he has held key roles as PI, *MedChem Unit Coordinator* or *Scientific Lead*, in **16 competitive projects** (IT and European) raising around 3.4 million Euros in research funds. Inside them, he is playing the Pi role in the prestigious *Science for Peace and Security Programme 2022*, funded by NATO. To these funds must be added 1.63 million Euros acquired from the *SpinOff Drug Discovery and Clinic s.r.l.* (see below) where he holds the role of CEO. See www.medsynth.unito.it for details.

Drug Discovery and Clinic (DDC) s.r.l. (2020 - present, www.DDCpharmaceutical.com) whose mission is to lead a new patented dihydroorotate dehydrogenase (*hDHODH*) inhibitor until human clinical trials for curing Acute Myeloid Leukemia (AML) and COVID-19.

Expertise: *Medicinal Chemistry, Drug Design, Synthetic Chemistry, Metabolism, Bioisosterism.*

Bibliometric indicators (upgraded June 2023):

Publications:	64
Patents:	6
Scopus:	Citations: 1296; H. Index:23
WOS,	Citations: 1242; H. Index: 23
ORCID iD:	https://orcid.org/0000-0002-3030-3163
Oral presentations	18 (+ over 100 other forms of meeting presentations)
Awards	6

Master / PhD teaching/Tutoring skills

Since 1999, he always played his educational roles (Master / PhD level) with great passion. At the present, he is in charge of two Courses (*Drug Analysis II* and *Drug Synthesis and Development Methodologies*, this latter at the Chemistry Dept of UniTO) involving almost 90 students and 190 h over two semesters. In recent years he had further refined his qualities as Advisor / Teacher, rationalizing them through the attendance of two UniTO courses, specifically dedicated to *advanced teaching techniques* enriched by the use of new technologies. He became skilled in training young scientist (**6** Post-Docs and more **90** Master students). Tutor panel of PhD course in *Pharmaceutical and Biomolecular Sciences* in the PhD School of Natural Sciences and Innovative Technologies at UniTO (**6** PhD students, in two occasions inside a *Double-Degree* PhD Agreement arranged between UniTO and the University of Copenhagen (DK)).

Department role (present)

- Member of Third Mission DSTF commission (focus of Patent, communication, metaverse)
- Member *Gruppo di Lavoro AQ per l'accreditamento AVA3 2023*